Tanezumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Tanezumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target NGF
Identifiers
CAS Number 880266-57-9 N
ATC code none
UNII EQL0E9GCX1 YesY
Synonyms RN624
Chemical data
Formula C6464H9942N1706O2026S46
Molecular mass 145.4 kg/mol
 NYesY (what is this?)  (verify)

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]

In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]

Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]

In march of 2012 the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.

A phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.[6]

References

  1. N05, American Medical Association.
  2. Lua error in package.lua at line 80: module 'strict' not found. 2009
  3. Lua error in package.lua at line 80: module 'strict' not found.
  4. http://www.genengnews.com/gen-news-highlights/trials-halted-as-pfizer-s-tanezumab-shown-to-worsen-osteoarthritis/81243572/
  5. Lua error in package.lua at line 80: module 'strict' not found.
  6. Lua error in package.lua at line 80: module 'strict' not found.

External links


<templatestyles src="Asbox/styles.css"></templatestyles>

<templatestyles src="Asbox/styles.css"></templatestyles>